Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Fig. 1

Cumulative risk of primary outcomes among PS-matched initiators of empagliflozin vs. GLP-1RA

CAPTION: The risks of cardiovascular mortality, MACE, and HHF were lower in the empagliflozin vs. GLP-1RA initiators. Cardiovascular mortality data was only available in the Medicare database

CV: cardiovascular; GLP-1RA: Glucagon-like peptide-1 receptor agonists; MACE: major adverse cardiovascular events; PS: propensity score

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840